Related Experiment Video
Updated: May 14, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Development of novel genetic cancer vaccines based on membrane-attached β2 microglobulin
Gal Cafri1, Alon Margalit, Esther Tzehoval
1Laboratory of Immunology, MIGAL Research Institute, Kiryat Shmona, Israel.
Abstract:
Cytotoxic T lymphocytes (CTLs) are the major effector arm of the immune system against tumors. Many tumor-associated antigens (TAAs), known today as potential rejection antigens, were identified by their ability to induce CTL responses. CTLs utilize their clonotypic T cell receptor (TCR) to recognize short antigenic peptides presented on major histocompatibility complex (MHC)-I proteins. These consist of a membrane-attached α heavy chain, which forms the peptide binding pocket, and a noncovalently associated β2m light chain, not anchored to the cell membrane. CTL activation requires that antigenic peptides be presented initially on professional antigen presenting cells (APCs), primarily dendritic cells (DCs). Autologous DCs are a powerful tool for the induction of antitumor responses and are thus widely explored as vehicles for cancer vaccines. Although encouraging evidence for the induction of tumor-specific CTLs by ex vivo-manipulated DCs came from numerous animal studies, reproducible objective clinical response in human trials is yet to be demonstrated.
Insights
Cytotoxic T lymphocytes (CTLs) are crucial for fighting tumors by recognizing tumor antigens. While dendritic cells (DCs) show promise in cancer vaccines for boosting CTLs, clinical success in humans remains elusive.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Cytotoxic T lymphocytes (CTLs) are key immune cells targeting tumors via T cell receptors (TCRs) recognizing peptide-MHC-I complexes.
- Tumor-associated antigens (TAAs) are identified by their capacity to elicit CTL responses.
- Dendritic cells (DCs) are professional antigen-presenting cells (APCs) essential for initiating CTL activation.
Purpose of the Study:
- To explore the potential of autologous dendritic cells (DCs) as cancer vaccines for inducing anti-tumor CTL responses.
- To review the current landscape of DC-based cancer vaccine strategies and their clinical translation.
Main Methods:
- Review of studies investigating the induction of CTL responses by ex vivo-manipulated DCs.
- Analysis of animal studies and human clinical trials involving DC-based cancer vaccines.
Main Results:
- Numerous animal studies demonstrate the efficacy of DCs in inducing tumor-specific CTLs.
- Clinical trials in humans have yet to consistently demonstrate reproducible objective clinical responses.
Conclusions:
- Ex vivo-manipulated DCs are a promising tool for cancer immunotherapy, effectively inducing tumor-specific CTLs in preclinical models.
- Further research and optimization are needed to translate the success of DC-based cancer vaccines into reproducible clinical benefits for human cancer patients.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...